Literature DB >> 29748446

BRAF V600E mutation detected in a case of Rosai-Dorfman disease.

Giancarlo Fatobene1, Julien Haroche2,3, Zofia Hélias-Rodzwicz4, Frédéric Charlotte2,3, Valérie Taly5, Aliana Meneses Ferreira1, André Néder Ramires Abdo5,6, Vanderson Rocha1,6,7, Jean-François Emile8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29748446      PMCID： PMC6068029          DOI： 10.3324/haematol.2018.190934

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.

Authors:  Jean-François Emile; Eli L Diamond; Zofia Hélias-Rodzewicz; Fleur Cohen-Aubart; Frédéric Charlotte; David M Hyman; Eunhee Kim; Raajit Rampal; Minal Patel; Chezi Ganzel; Shlomzion Aumann; Gladwys Faucher; Catherine Le Gall; Karen Leroy; Magali Colombat; Jean-Emmanuel Kahn; Salim Trad; Philippe Nizard; Jean Donadieu; Valérie Taly; Zahir Amoura; Omar Abdel-Wahab; Julien Haroche
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

2.  Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.

Authors:  Lynn H Lee; Anjelika Gasilina; Jayeeta Roychoudhury; Jason Clark; Francis X McCormack; Joseph Pressey; Michael S Grimley; Robert Lorsbach; Siraj Ali; Mark Bailey; Philip Stephens; Jeffrey S Ross; Vincent A Miller; Nicolas N Nassar; Ashish R Kumar
Journal:  JCI Insight       Date:  2017-02-09

3.  High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Authors:  Julien Haroche; Frédéric Charlotte; Laurent Arnaud; Andreas von Deimling; Zofia Hélias-Rodzewicz; Baptiste Hervier; Fleur Cohen-Aubart; David Launay; Annette Lesot; Karima Mokhtari; Danielle Canioni; Louise Galmiche; Christian Rose; Marc Schmalzing; Sandra Croockewit; Marianne Kambouchner; Marie-Christine Copin; Sylvie Fraitag; Felix Sahm; Nicole Brousse; Zahir Amoura; Jean Donadieu; Jean-François Emile
Journal:  Blood       Date:  2012-08-09       Impact factor: 22.113

4.  How I treat Langerhans cell histiocytosis.

Authors:  Carl E Allen; Stephan Ladisch; Kenneth L McClain
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

5.  Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease.

Authors:  Matthias S Matter; Michel Bihl; Darius Juskevicius; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2017-06-09       Impact factor: 4.064

6.  Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.

Authors:  Sofia Garces; L Jeffrey Medeiros; Keyur P Patel; Shaoying Li; Sergio Pina-Oviedo; Jingyi Li; Juan C Garces; Joseph D Khoury; C Cameron Yin
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

Review 7.  Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Authors:  Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss
Journal:  Blood       Date:  2016-03-10       Impact factor: 22.113

8.  Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.

Authors:  Eric Jacobsen; Vignesh Shanmugam; Jyothi Jagannathan
Journal:  N Engl J Med       Date:  2017-12-14       Impact factor: 91.245

9.  Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis.

Authors:  Marco Chilosi; Fabio Facchetti; Anna Caliò; Alberto Zamò; Matteo Brunelli; Guido Martignoni; Andrea Rossi; Licia Montagna; Paola Piccoli; Alessandra Dubini; Andrea Tironi; Sara Tomassetti; Venerino Poletti; Claudio Doglioni
Journal:  Leuk Lymphoma       Date:  2014-03-10

10.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113
View more
  16 in total

1.  BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor.

Authors:  Rosemarie Mastropolo; Allison Close; Steven W Allen; Kenneth L McClain; Scott Maurer; Jennifer Picarsic
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Authors:  Matthias Papo; Fleur Cohen-Aubart; Ludovic Trefond; Adeline Bauvois; Zahir Amoura; Jean-François Emile; Julien Haroche
Journal:  Curr Oncol Rep       Date:  2019-05-21       Impact factor: 5.075

3.  Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up.

Authors:  Sonia Mahajan; Reiko Nakajima; Mariko Yabe; Ahmet Dogan; Gary A Ulaner; Joachim Yahalom; Ariela Noy; Eli L Diamond; Heiko Schöder
Journal:  Clin Nucl Med       Date:  2020-06       Impact factor: 7.794

4.  Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1.

Authors:  Jérôme Razanamahery; Eli L Diamond; Fleur Cohen-Aubart; Karl-Heinz Plate; Giota Lourida; Frederic Charlotte; Zofia Hélias-Rodzewicz; Gaurav Goyal; Ronald S Go; Ahmet Dogan; Omar Abdel-Wahab; Benjamin Durham; Neval Ozkaya; Zahir Amoura; Jean-Francois Emile; Julien Haroche
Journal:  Haematologica       Date:  2019-05-23       Impact factor: 9.941

Review 5.  MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age.

Authors:  Rikhia Chakraborty; Omar Abdel-Wahab; Benjamin H Durham
Journal:  Cold Spring Harb Perspect Med       Date:  2021-05-03       Impact factor: 6.915

Review 6.  Histiocytosis.

Authors:  Jean-François Emile; Fleur Cohen-Aubart; Matthew Collin; Sylvie Fraitag; Ahmed Idbaih; Omar Abdel-Wahab; Barrett J Rollins; Jean Donadieu; Julien Haroche
Journal:  Lancet       Date:  2021-04-23       Impact factor: 202.731

7.  Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion.

Authors:  Shaimaa S Eissa; Michael R Clay; Teresa Santiago; Gang Wu; Lu Wang; Barry L Shulkin; Jennifer Picarsic; Kim E Nichols; Patrick K Campbell
Journal:  Blood Adv       Date:  2020-07-14

8.  BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.

Authors:  J Picarsic; T Pysher; H Zhou; M Fluchel; T Pettit; M Whitehead; L F Surrey; B Harding; G Goldstein; Y Fellig; M Weintraub; B C Mobley; P M Sharples; M L Sulis; E L Diamond; R Jaffe; K Shekdar; M Santi
Journal:  Acta Neuropathol Commun       Date:  2019-11-04       Impact factor: 7.801

9.  NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.

Authors:  Kuan-Jou Wu; Shu-Hao Li; Jia-Bin Liao; Chien-Chun Chiou; Chieh-Shan Wu; Chien-Chin Chen
Journal:  Biology (Basel)       Date:  2021-05-02

10.  [Rosai-Dorfman disease: a clinicopathologic analysis and whole exome sequencing in 23 cases].

Authors:  W J Fu; J Du; J Lu; L Z Wang; J M Yang; M X He; X X Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.